YichenWu

Associate

Beijing + 86.10.5866.1228

Connect:

Share

As part of the Firm's Antitrust Practice, Yichen Wu focuses his practice on international merger clearance and antitrust investigation and litigation. His experience includes a number of cutting-edge cases involving the intersection of antitrust and intellectual property law.

Yichen assists clients in connection with antitrust issues that arise throughout the merger and acquisition process, from premerger counseling through in-depth investigations across different jurisdictions. In addition to representing clients in antitrust investigations before authorities in China, Yichen counsels on antimonopoly compliance in the United States, EU, Japan, Korea, and other jurisdictions and advises on global corporate compliance programs.

Prior to joining Jones Day in 2017, Yichen worked as an antitrust associate in the Washington, D.C. office of a leading international law firm for more than three years, where he served companies in the software, biotechnology, pharmaceutical, semiconductor, telecommunications, computer hardware, internet infrastructure, and e-commerce industries. He also conducted internal compliance and government investigations for violations of the Foreign Corrupt Practices Act (FCPA) and represented companies in obtaining clearance before the Committee on Foreign Investment in the United States (CFIUS).

Experience

  • JERA acquires minority stake in Formosa 1 offshore wind power projectJones Day advised JERA in the acquisition of a minority stake in the Formosa 1 offshore wind power project, located off the north-western coast of Taiwan.
  • LORD Corporation acquired by Parker Hannifin for $3.675 billionJones Day advised LORD Corporation in its $3.675 billion acquisition by Parker Hannifin Corporation.
  • USG acquired by Gebr. Knauf for $7 billionJones Day advised USG Corporation in the acquisition by Gebr. Knauf KG ("Knauf") of all of the outstanding shares of USG in a transaction valued at $7 billion.
  • Oclaro sold to Lumentum for $1.8 billion in cash and stockJones Day advised Oclaro, Inc. in its $1.8 billion acquisition by Lumentum Holdings Inc.
  • Greystar recapitalizes Chapter student accommodation portfolio in Central LondonJones Day advised Greystar Real Estate Partners, LLC in a recapitalization of its and PSP’s Chapter portfolio of student accommodation properties, one of the largest in Central London, by consolidating the portfolio under a new joint venture in which Allianz acquired an interest.
  • Glencore Singapore forms joint venture with Zhejiang Provincial PetroleumJones Day advised Glencore Singapore Pte. Ltd. on the formation of Zhejiang Petroleum Trading Co., Ltd., a joint venture with Zhejiang Provincial Petroleum Co., Ltd.
  • Safran completes €8.7 billion agreed tender offer targeting Zodiac Aerospace's shares creating global leader in aircraft equipmentJones Day represented Safran in connection with its €8.7 billion agreed tender offer targeting Zodiac Aerospace's shares to create a global leader in aircraft equipment.
  • PotashCorp combines with Agrium in $38 billion merger-of-equalsJones Day advised PotashCorp in its $38 billion all-stock merger-of-equals with Agrium.
  • Koch Disruptive Technologies leads $150 million investment in INSIGHTECJones Day advised Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies, as the lead investor in a $150 million Series E funding round for INSIGHTEC, a commercial stage medical device company.
  • Ambry Genetics sold to joint venture formed by Konica Minolta and Innovation Network for up to $1.0 billionJones Day advised Ambry Genetics Corporation, a leading genetic testing corporation, in its sale to a newly formed joint venture between Konica Minolta, Inc. and Innovation Network Corporation of Japan for up to $1.0 billion (including earnouts).
  • Imerys merger with Kerneos receives antitrust clearanceJones Day represented Imerys S.A., a multinational manufacturer of industrial minerals, on the antitrust aspects of its €880 million acquisition of Kerneos, a global producer and supplier of specialty cements.
  • Sanofi and Lonza form joint venture to establish large-scale biologics production facility in SwitzerlandJones Day advised Sanofi in the formation of a joint venture with Lonza Group AG to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
    • View All

    September 2018 Commentaries

    Chinese Courts Stick to "Rule of Reason" in Resale Price Maintenance Civil Actions

    March 2018 Jones Day Publications

    How China Deals with the Diverging Approaches to Monopoly Agreements

    October 2017 Commentaries

    Chinese Competition Authority Imposes Fines for Price-Fixing Involving Industry Associations
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.